Skip to main content

Adenoviruses are being explored as vectors for vaccines against various infectious diseases, such as COVID-19, and as vectors for gene therapy purposes against many heritable diseases. The efficacy of adenoviral vectors depends in part on their functional interactions with receptors on host cells as this predetermines which tissues or organs can be targeted. Together with our collaborators from the research group of Dr. Niklas Arnberg (Division of Virology Umea University, Sweden), and the Institute of Biochemistry at the University of Tübingen, we report on our findings that human adenoviruses from subgroup D can utilize their hexon capsid protein for cell entry, a mechanism formerly exclusively attributed to the fiber capsid protein.

Link to full article published in PNAS.